This observational study is looking at how the body's natural defenses (immune system) and the tiny living organisms (microbiota) in your airways and gut might affect how well immunotherapy works for advanced non-small cell lung cancer. Researchers will collect samples like blood, stool, and from your airways to see if certain patterns in these samples can predict how you respond to PD-1 blockade treatment. You may be able to join if you have advanced non-small cell lung cancer and are starting PD-1 blockade treatment, either alone or with chemotherapy. The study will look at how long you live without your cancer getting worse (progression-free survival) and changes in your microbiota over three years. The current recruitment status is unclear.

Study design

This is an observational study planning to enroll 48 participants. It will collect samples and information over time to understand how different factors relate to treatment outcomes.

What's involved

You would have an electrocardiogram, blood work, X-ray, and lung function tests. You would also provide a stool collection kit and undergo a research bronchoscopy to sample your airways.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for three years to assess progression-free survival and changes in microbiota signatures.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.